Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...
Valneva SE (“Valneva”) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) ...
Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.
The US Food and Drug Administration (FDA) has approved Bavarian Nordic’s chikungunya vaccine Vimkunya for use in individuals ...
Valneva expects further sales growth this year after it posted higher revenue in 2024.
Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback